Key Terms

A way to read carefully

Terms are not conclusions.

In this glossary, parenthetical labels identify the setting of the evidence: in vitro, preclinical, human case report, or clinical trial. Those settings answer different questions and cannot be assumed to mean the same thing.

For a broader orientation to this subject, the Arenvia overview of ibogaine and noribogaine provides context before individual terms are considered. The language below also complements the site’s mechanism-by-mechanism explanations.

A
B
C
D
E
G
H
I
K
M
N
O
P
Q
R
S
T
V

A–H

Molecules, metabolism, and channels

These entries describe how a compound may be transformed, distributed, or studied at molecular targets. Cross-references point to terms that are often discussed together.

Absorption

The movement of a substance from its administration site into systemic circulation. Rate and extent of absorption can affect exposure, but this term does not predict benefit or safety on its own. (Human pharmacokinetic studies)

Acute toxicity

Harmful effects occurring after a single exposure or brief period of exposure. In ibogaine discussions, this broad term can include neurological, cardiovascular, and other adverse effects. (Preclinical, human case report)

Bioactivation

Metabolic conversion of a compound into another biologically active compound. Ibogaine’s conversion to noribogaine is commonly described this way; see noribogaine and CYP2D6. (In vitro, human pharmacokinetic studies)

Bioavailability

The fraction of an administered dose that reaches systemic circulation unchanged. It can vary with route, metabolism, co-exposures, and individual factors. (Human pharmacokinetic studies)

Cardiac ion channel

A membrane protein that helps regulate electrically charged particles in heart cells. Effects on particular channels can change cardiac electrical activity; see hERG and QTc. (In vitro, clinical electrophysiology)

CYP2D6

A cytochrome P450 enzyme involved in metabolizing many medicines, including pathways relevant to ibogaine. Genetic variation and enzyme inhibition can alter concentrations of ibogaine and noribogaine. (In vitro, human pharmacokinetic studies)

Drug–drug interaction

A change in a substance’s effect or concentration caused by another substance. Interactions may be pharmacokinetic, such as enzyme inhibition, or pharmacodynamic, such as overlapping cardiac effects. (In vitro, clinical pharmacology)

Elimination half-life

The time associated with a 50% reduction in a measured concentration during an elimination phase. It is a pharmacokinetic descriptor, not a direct measure of duration of subjective or clinical effects. (Human pharmacokinetic studies)

GDNF

Glial cell line-derived neurotrophic factor, a protein involved in neuronal development and maintenance. Changes in GDNF-related signaling have been explored in laboratory and animal research, without establishing a therapeutic effect in people. (Preclinical)

hERG

The human ether-à-go-go-related gene, commonly used as shorthand for a potassium channel important in cardiac repolarization. Inhibition of this channel is a recognized concern in drug-safety evaluation; see QTc and torsades de pointes. (In vitro, human case report)

Why hERG matters here

hERG is a laboratory term with practical relevance because it connects a molecular observation to a potential cardiac-risk pathway. The International Council for Harmonisation efficacy guidelines include internationally recognized guidance concerning clinical QT/QTc evaluation.

hERG refers to a specific cardiac potassium channel.
Channel inhibition can be relevant to delayed repolarization.
It is not a diagnosis and does not by itself predict an outcome for one person.
Its meaning depends on concentration, co-exposures, physiology, and other evidence.

Calm close perspective paired with definitions of receptors and signaling in ibogaine neuropharmacology — Receptor terms describe a target or a proposed action, not a settled clinical result.

I–N

Receptors and signaling language

In vitro

Research performed outside a living organism, such as in cells, tissue preparations, or laboratory assays. It can identify molecular interactions but cannot alone establish human effects. (Evidence type)

Kappa opioid receptor

An opioid receptor subtype involved in signaling pathways distinct from the mu opioid receptor. Ibogaine- and noribogaine-related activity at this target has been investigated in experimental systems; see partial agonist. (In vitro, preclinical)

Ligand

A molecule that binds to a receptor, channel, transporter, or other target. Binding does not by itself specify whether the ligand activates, blocks, or otherwise modulates that target. (In vitro)

Metabolite

A compound produced when the body chemically transforms another compound. Noribogaine is a principal metabolite of ibogaine; see bioactivation. (Human pharmacokinetic studies)

Mu opioid receptor

An opioid receptor subtype relevant to the actions of many opioid drugs. Findings involving ibogaine-related compounds at this target are complex and should not be equated with conventional opioid agonism. (In vitro, preclinical)

Noribogaine

An active metabolite formed from ibogaine, with pharmacology that differs from the parent compound. It is frequently discussed because its persistence and target profile may contribute to overall exposure and risk considerations. (In vitro, human pharmacokinetic studies)

NMDA receptor

A subtype of glutamate receptor and ion channel involved in excitatory signaling. It is widely studied in neuroscience; ibogaine has been described as interacting with this receptor channel in experimental work. (In vitro, preclinical)

NMDA open-channel antagonist

A compound that blocks an NMDA receptor channel when the channel is open. This describes a mechanism observed in experimental systems and does not, by itself, establish a human therapeutic outcome. (In vitro)

Why noribogaine matters here

Noribogaine helps explain why describing ibogaine as one molecule can be incomplete. The NCBI overview of pharmacokinetics outlines why metabolism and exposure are central to understanding drug effects.

It is a metabolite, not simply another name for ibogaine.
Its concentrations may follow a different time course than the parent compound.
It has its own laboratory target profile.
Its relevance does not convert preclinical observations into clinical proof.

O–S

Exposure, transporters, and study types

The same word can carry a different weight depending on whether it comes from a cell assay, animal model, human case report, or controlled clinical research.

Off-target effect

An interaction with a biological target other than the target initially emphasized. Because ibogaine and noribogaine have broad pharmacology, off-target actions are part of interpreting both possible effects and risks. (In vitro, preclinical)

Partial agonist

A ligand that activates a receptor but produces less than the maximal response possible at that receptor under defined experimental conditions. “Kappa partial agonist” therefore describes a relative laboratory action, not a clinical recommendation. (In vitro, preclinical)

Pharmacodynamics

The study of what a substance does to the body, including target interactions and biological responses. It differs from pharmacokinetics, which concerns what the body does to a substance. (Clinical pharmacology)

Pharmacokinetics

The study of absorption, distribution, metabolism, and elimination of a substance over time. It provides an exposure framework but does not alone establish safety or efficacy. (Human pharmacokinetic studies)

Plasma protein binding

The reversible attachment of a substance to proteins in blood plasma. Protein binding can influence the proportion of unbound compound available for distribution or interaction with targets. (In vitro, human pharmacokinetic studies)

Preclinical

Research conducted before or outside clinical testing in people, often using laboratory systems or animal models. It can support mechanistic hypotheses but has important limits for predicting human outcomes. (Evidence type)

QTc

A heart-electrical measurement representing the QT interval corrected for heart rate. QTc prolongation is a safety signal that may be relevant to arrhythmia risk; see hERG and torsades de pointes. (Clinical electrophysiology, human case report)

Receptor affinity

A measure describing how strongly a ligand binds a target under defined conditions. Affinity does not necessarily indicate functional activity, selectivity, dose in people, or clinical effect. (In vitro)

Reuptake inhibition

Reduced transport of a neurotransmitter back into a nerve cell after release. Noribogaine has been studied for effects on serotonin transport; see SERT. (In vitro, preclinical)

SERT

The serotonin transporter, a protein that helps regulate serotonin signaling by transporting serotonin from the synaptic space into cells. Laboratory findings about SERT concern a molecular target and should not be read as proof of a clinical effect. (In vitro, preclinical)

Serotonin transporter inhibition

Reduced activity of SERT, which can alter serotonin signaling in experimental systems. The result depends on context, concentration, timing, and the broader pharmacology of a compound. (In vitro, preclinical)

Selectivity

The degree to which a compound affects one target more than others under specified conditions. Lower selectivity can make single-target explanations incomplete. (In vitro)

Why QTc matters here

QTc is a clinical measurement rather than a receptor label. Its interpretation is technical and context-dependent; the Long QT syndrome overview explains the relationship between prolonged ventricular repolarization and vulnerability to serious rhythm disturbances.

QTc is a corrected ECG interval, not a diagnosis by itself.
Its measurement and interpretation can vary with method and context.
Multiple substances and health factors can affect cardiac electrical risk.
A discussion of QTc should not be treated as individualized medical guidance.

T–V

Safety language and uncertainty

Safety terms can sound definitive when they are not. They identify patterns or possibilities that require careful interpretation, especially in the presence of individual variability and interacting substances.

Torsades de pointes

A specific form of potentially dangerous polymorphic ventricular tachycardia, often discussed in connection with QT prolongation. The phrase describes an arrhythmia pattern and should be understood alongside QTc and hERG. (Clinical electrophysiology, human case report)

Transporter

A protein that moves a substance across a cell membrane. SERT is a transporter; transporter activity is one way a compound may influence neurotransmitter signaling. (In vitro)

Ventricular arrhythmia

An abnormal heart rhythm arising from the lower chambers of the heart. This is a clinical term, not a conclusion that a particular exposure will cause an arrhythmia. (Clinical electrophysiology, human case report)

Volume of distribution

A pharmacokinetic parameter relating the amount of a substance in the body to its measured plasma concentration. It is a model-based descriptor rather than a literal anatomical volume. (Human pharmacokinetic studies)

Clinical trial

A structured study involving people that follows a defined protocol. Trial quality, size, comparison group, population, and outcome measures all affect what a result can support. (Evidence type)

Human case report

A detailed account of an individual clinical event or experience. It can identify a signal or raise a question, but it generally cannot establish frequency, causality, or comparative efficacy. (Evidence type)

Why CYP2D6 matters here

CYP2D6 illustrates the difference between a mechanism and a prediction. Information on safety factors requiring careful interpretation can help situate this enzyme within the wider questions of metabolism, interactions, and uncertainty.

People can differ in CYP2D6 activity because of genetics and co-exposures.
Some substances can inhibit or otherwise alter enzyme activity.
Different metabolism can change measured exposure to parent compound and metabolite.
Knowing the term does not make it possible to assess an individual’s risk outside appropriate clinical care.

Context beyond a definition

Use precise words without overstating what they mean.

Technical terms often appear beside practical questions about trauma, alcohol use, detoxification, travel, legality, clinics, or cost. Those contexts can carry different evidence and safety questions from the molecular terms collected here.

A glossary is most useful when it makes uncertainty easier to see—not when it makes uncertainty disappear.

For example, people encountering claims about ibogaine therapy for PTSD may see receptor terminology that does not establish clinical efficacy. Questions about whether ibogaine is illegal in the USA are legal and policy questions, separate from pharmacodynamic definitions.

Descriptions of top ibogaine treatment centers, ibogaine treatment in Europe, and an ibogaine Mexico retreat should not substitute for independent appraisal of medical, regulatory, or emergency-care questions.

Likewise, phrases about ibogaine for alcohol addiction, ibogaine detox centers, or an ibogaine clinic in Tijuana often place scientific language beside decisions that may involve serious risk. Cost information, including ibogaine cost considerations, is also distinct from evidence about mechanisms or outcomes.

Arenvia’s approach to independence and evidence limits explains why the site separates definitions from claims. For background on why dose, metabolism, and individual differences can matter across drugs, see the National Institute of General Medical Sciences pharmacology fact sheet.

Common reading questions

A short guide to using the glossary

The answers below reinforce the limits of term-based interpretation and explain what the evidence labels are intended to communicate.

Does a glossary establish that ibogaine works for a condition?

No. Definitions describe the meaning and limits of terms used in neuropharmacology; they do not establish therapeutic efficacy or replace clinical evidence. A molecular mechanism can be scientifically interesting without demonstrating a clinical outcome.

Why are hERG, QTc, CYP2D6, and noribogaine emphasized?

These terms connect pharmacology with exposure and cardiac-risk questions. They are important for interpreting why ibogaine discussions often stress uncertainty, interactions, and individualized medical assessment.

What does a stated evidence type mean?

Evidence labels identify the setting in which a finding was observed, such as in vitro, preclinical, human case report, or clinical trial. They should not be treated as interchangeable, because each setting has different strengths and limits.